Skip to main content

Advertisement

Table 3 Comparison of treatment outcomes of MDR/XDR-TB cases according to daily administered linezolid dose

From: Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis

Outcome ≤600 mg linezolid n (%) >600 mg linezolid n (%) Difference (%) (95 % CI) p value
Culture conversion 184/215 (85.58) 39/41 (95.12) 9.54 (−2.29–16.32 %) p = 0.0948
Treatment success 134/176 (76.14) 34/38 (89.47) 13.34 (−13.22–23.12 %) p = 0.0695
Myelosuppression 47/240 (19.58) 24/48 (50.00) 30.42 (15.77–44.94 %) p < 0.0001
Neuropathy 82/240 (34.17) 20/48 (41.67) 7.5 % (−6.84–22.79 %) p = 0.3213
Linezolid discontinuation 40/222 (18.02) 9/48 (18.75) 0.73 % (−9.66–14.72 %) p = 0.9050